Answers are grounded in this paper and cite their sources.
RIBANNA is a German prospective, non-interventional study assessing the efficacy and safety of RIB + AI/FUL, endocrine therapy (ET) or chemotherapy (CT) in 1st line (1L) and subsequent therapy lines in pre-, peri-and postmenopausal women with HR+, HER2- advanced breast cancer. Real-world data on treatment sequence resulting from the 6th IA will be presented. Patients (Pts) were treated according to German treatment guidelines and data on 1L and subsequent therapy lines were collected. Parameters that influence treatment decision for second-line (2L) therapy following 1L RIB were analysed including: Baseline characteristics, the median progression-free survival (mPFS) in 1L and patient-reported outcomes (EORTC QLQ-C30/BR23). At data cutoff (9. Oct 2023), 2113 pts were enrolled in the study (RIB + AI/FUL, n = 1799; ET, n = 179; CT, n = 135) and overall, 843 pts progressed to 2L therapy (median follow-up 2.9 years). Out of 709 pts (39.4%) with 1L RIB + AI/FUL having progressed, 89 pts also received RIB + AI/FUL as 2L therapy, 280 ET, 290 CT and 50 other treatments. Decision on 2L treatment seemed to be associated by the time to 1st progression, as 58% of pts with a 1L progression ≤ 6 months were in the RIB(1L)-CT(2L) group, whereas 59.8% of pts that progressed in 1L > 24 months were in the RIB-RIB or RIB-ET group. PFS analysis in 1L demonstrated that pts receiving 2L CT had the shortest mPFS (RIB-RIB, PFS = 14.5 months; RIB-ET, PFS = 19.4 months; RIB-CT PFS = 12.2 months). Also, TFI (time from the end of adjuvant therapy to disease recurrence) influenced 2L therapy decisions (TFI ≤ 12 months; RIB-RIB = 28.1%; RIB-ET = 27.5%; RIB-CT = 36.6%), suggesting a shorter TFI led more frequently to 2L CT. ECOG performance status at baseline, EORTC QLQ-C30/BR23 scores and incidence of AEs during RIB + AI/FUL 1L therapy of pts seemed to not influence 2L therapy decision. Current data suggest, that 2L treatment decisions were influenced by the time to 1st progression/PFS and the TFI duration. Pts with a rapid progression (enriched in this analysis) were more likely treated with CT, than ET or RIB. Data will be analysed in the future once all pts have progressed in 1L.
No takes yet. Share an insight, caveat, or question.
Lüftner et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: